Announcements Trials
Browse Landscape

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Part 1:r/r B-cell Malignancies 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 37Etoposide 25Vincristine 24Cytarabine 21Doxorubicin 19Rituximab 17Radiotherapy 17Peripheral Blood Stem Cell Transplantation 16Melphalan 16Prednisolone 14Methotrexate 14Filgrastim 13fludarabine phosphate 11Prednisone 11Dexamethasone 11Carmustine 9Bleomycin 9pegylated granulocyte colony-stimulating factor 8Cyclosporine 8Busulfan 8fludarabine 7Ifosfamide 7Cisplatin 7sargramostim 6Vinblastine 6Mitoxantrone 6Methylprednisolone 6Gemcitabine 6Chlorambucil 6Antilymphocyte Serum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma × orelabrutinib × Clear all
NCT06015464 2023-08-29

An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

The First Affiliated Hospital with Nanjing Medical University

Unknown
81 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡